Business Wire

Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate

-- Data in non-human primates from C100 program show potent stem and immune cell depletion with anti-CD45 amanitin ADC that is well tolerated at efficacious doses -- -- C200 development candidate, ...
Business Wire

Magenta Therapeutics’ Lead Targeted Antibody Drug Conjugate Shows Promising Preclinical Results for Non-Genotoxic Conditioning for Bone Marrow Transplant

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today ...
Nasdaq

Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, ...
ascopubs.org

Effect of pesticide exposure on HER-2/neu and CD117 overexpression in patients with extensive stage small cell lung carcinoma (ESSCLC)

Using novel protein antibodies on tissue microarrays (TMAs) for breast cancer prognostication This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full ...